A composition for improving intestinal health and methods of making and using the same

Abstract

The present application relates to the technical field of feed additive, in particular to a composition for improving intestinal health and a preparation method and application thereof.The composition comprises the following components by mass fraction: apple dietary fiber powder 10-30 parts, pea dietary fiber powder 10-30 parts, celery dietary fiber powder 10-30 parts, cat grass powder 10-30 parts, beer yeast 5-20 parts, fish oil 10-20 parts and sodium alginate 5-15 parts.The present application comprises high-fiber substances by using apple dietary fiber powder, pea dietary fiber powder and celery dietary fiber powder in a suitable proportion, and then compounding cat grass powder, beer yeast, fish oil and sodium alginate in a suitable proportion, so that the obtained composition can indirectly improve the absorption capacity of the intestinal tract, improve the intestinal health condition, relieve intestinal inflammation and promote digestion and absorption.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of feed additives, in particular to a composition for improving intestinal health and a preparation method and application thereof. BACKGROUND

[0002] With the development of pet economy, the pet food, especially the pet cat food, is changing constantly at home and abroad, and the life quality and health of pets are paid more and more attention. People begin to look for more healthy and nutritious food for pet cats, which greatly promotes the development of pet food. Most of the various pet foods on the market have low nutritional value, have adverse effects on the growth and development of pet cats, are not easy to digest, and are not easy to absorb nutrients, which can easily cause intestinal inflammation. Moreover, after the cat has intestinal inflammation, drug treatment is generally used, which treats the symptoms but not the root cause and is harmful to health. SUMMARY

[0003] In order to solve the above problems, the present application provides a composition for improving intestinal health and a preparation method and application thereof. The composition provided by the present application can relieve intestinal inflammation and promote digestion and absorption, and has the effect of improving intestinal health.

[0004] In order to achieve the above purpose, the present application provides the following technical scheme:

[0005] The present application provides a composition for improving intestinal health, which comprises the following components in mass parts: 10-30 parts of apple dietary fiber powder, 10-30 parts of pea dietary fiber powder, 10-30 parts of celery dietary fiber powder, 10-30 parts of cat grass powder, 5-20 parts of beer yeast, 10-20 parts of fish oil and 5-15 parts of sodium alginate.

[0006] Preferably, the composition comprises the following components in mass parts: 15 parts of apple dietary fiber powder, 15 parts of pea dietary fiber powder, 10 parts of celery dietary fiber powder, 15 parts of cat grass powder, 5 parts of beer yeast, 10 parts of fish oil and 15 parts of sodium alginate.

[0007] Preferably, the composition comprises the following components in mass parts: 20 parts of apple dietary fiber powder, 20 parts of pea dietary fiber powder, 10 parts of celery dietary fiber powder, 20 parts of cat grass powder, 10 parts of beer yeast, 10 parts of fish oil and 10 parts of sodium alginate.

[0008] Preferably, the composition comprises the following components in mass parts: 25 parts of apple dietary fiber powder, 25 parts of pea dietary fiber powder, 15 parts of celery dietary fiber powder, 15 parts of cat grass powder, 15 parts of beer yeast, 10 parts of fish oil and 15 parts of sodium alginate.

[0009] Preferably, the size of the apple dietary fiber powder, the pea dietary fiber powder, the celery dietary fiber powder, the cat grass powder, the beer yeast and the sodium alginate is ≤80 mesh, respectively.

[0010] This invention provides a method for preparing the composition described in the above technical solution, comprising the following steps:

[0011] The composition is obtained by mixing apple dietary fiber powder, pea dietary fiber powder, celery dietary fiber powder, cat grass powder, brewer's yeast, fish oil and sodium alginate in a certain proportion.

[0012] Preferably, the mixing process further includes granulation to obtain a composition product in the form of soft particles; the soft particles have a diameter of 0.5~1cm and a thickness of 0.5~1cm.

[0013] Preferably, the extrusion temperature of the granulation is 40~80℃.

[0014] The present invention provides the application of the composition described in the above technical solution or the composition prepared by the preparation method described in the above technical solution in the preparation of feed additives that promote intestinal health.

[0015] Preferably, the promotion of gut health includes: relieving intestinal inflammation and / or promoting digestion and absorption.

[0016] Beneficial effects:

[0017] This invention provides a composition for improving gut health, comprising the following components in parts by weight: 10-30 parts apple dietary fiber powder, 10-30 parts pea dietary fiber powder, 10-30 parts celery dietary fiber powder, 10-30 parts cat grass powder, 5-20 parts brewer's yeast, 10-20 parts fish oil, and 5-15 parts sodium alginate. This invention uses a suitable proportion of apple dietary fiber powder, pea dietary fiber powder, and celery dietary fiber powder to create a high-fiber composition, which is then further combined with a suitable proportion of cat grass powder, brewer's yeast, fish oil, and sodium alginate. The resulting composition can indirectly improve intestinal absorption capacity, improve gut health, alleviate intestinal inflammation, and promote digestion and absorption. Attached Figure Description

[0018] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0019] Figure 1 Waltham stool scoring chart;

[0020] Figure 2 The results of fecal scores from different groups of cats in the safety evaluation test;

[0021] Figure 3 The results of weight measurements of cats in different groups during the safety evaluation test;

[0022] Figure 4The results of weight measurements of cats in different groups during the functional validation test;

[0023] Figure 5 The fecal scores of different groups of cats in the functional validation test;

[0024] Figure 6 The results of fecal odor measurement in different groups during the functional validation test;

[0025] Figure 7 The results of intestinal inflammation marker measurements in different groups of cats on day 42 during the functional validation trial;

[0026] Figure 8 The results of SCFAs index measurement in different groups of cats on day 42 in the functional validation trial;

[0027] Figure 9 The results of fecal microbial sequencing analysis at the cat phylum level in different groups during the functional validation trial;

[0028] Figure 10 The results of fecal microbial sequencing analysis at the feline level in different groups during the functional validation trial;

[0029] Figure 11 This is the result of fecal microbial sequencing analysis at the fecal genus level in different groups during the functional validation test. Detailed Implementation

[0030] The present invention provides a composition for improving gut health, comprising the following components in parts by weight: 10-30 parts apple dietary fiber powder, 10-30 parts pea dietary fiber powder, 10-30 parts celery dietary fiber powder, 10-30 parts cat grass powder, 5-20 parts brewer's yeast, 10-20 parts fish oil, and 5-15 parts sodium alginate.

[0031] Unless otherwise specified, the present invention does not have any special requirements on the source of each component of the composition, and commercially available products well known to those skilled in the art can be used.

[0032] The composition of this invention comprises 10-30 parts by weight, preferably 15-25 parts, and more preferably 25 parts of apple dietary fiber powder; the size of the apple dietary fiber powder is preferably ≤80 mesh, and more preferably apple dietary fiber powder that can pass through an 80-mesh sieve. The apple dietary fiber powder of this invention is preferably purchased from Xi'an Guanmao Biotechnology Co., Ltd., product number 1024-3. The apple dietary fiber powder of this invention helps promote gastrointestinal motility.

[0033] Based on the weight of the apple dietary fiber powder, the composition of this invention includes 10-30 parts of pea dietary fiber powder, preferably 15-25 parts, more preferably 25 parts; the size of the pea dietary fiber powder is preferably ≤80 mesh, more preferably pea dietary fiber powder that can pass through an 80 mesh sieve. The pea dietary fiber powder of this invention is preferably purchased from PeptideBio (Beijing) Co., Ltd., product number HT22021121. The pea dietary fiber powder of this invention has the effects of improving immunity, relieving constipation, and accelerating metabolism.

[0034] Based on the weight of the apple dietary fiber powder, the composition of this invention includes 10-30 parts of celery dietary fiber powder, preferably 10-15 parts, more preferably 15 parts; the size of the celery dietary fiber powder is preferably ≤80 mesh, more preferably celery dietary fiber powder that can pass through an 80-mesh sieve. The celery dietary fiber powder of this invention is preferably purchased from Shaanxi Zhenhe Biotechnology Co., Ltd., product number ZH606-29. The celery dietary fiber powder of this invention has the effects of lowering blood pressure and promoting gastrointestinal motility.

[0035] This invention uses a suitable blend of apple dietary fiber powder, pea dietary fiber powder, and celery dietary fiber powder to obtain a composite fiber powder with a high fiber content, which is beneficial to intestinal health, promotes the digestion and absorption of nutrients, and protects the gastric mucosa.

[0036] Based on the weight of the apple dietary fiber powder, the composition of this invention includes 10-30 parts of cat grass powder, preferably 15-20 parts, more preferably 15 parts; the cat grass powder preferably has a size ≤80 mesh, more preferably cat grass powder that can pass through an 80-mesh sieve. The cat grass powder of this invention is preferably purchased from Xi'an Zebang Biotechnology Co., Ltd., product number XAZB54180. The cat grass powder of this invention has the effect of enhancing the digestive function of cats.

[0037] Based on the weight of the apple dietary fiber powder, the composition of this invention includes 5-20 parts of brewer's yeast, preferably 5-15 parts, more preferably 15 parts; the size of the brewer's yeast is preferably ≤80 mesh, more preferably brewer's yeast that can pass through an 80-mesh sieve. The brewer's yeast of this invention is preferably purchased from Shanxi Hongxing Biotechnology Co., Ltd., product number HX-0614-443. The brewer's yeast of this invention can enhance the taste and palatability of the composition.

[0038] Based on the weight of the apple dietary fiber powder, the composition of this invention includes 10-20 parts of fish oil, preferably 10-15 parts, and more preferably 10 parts. The fish oil of this invention is preferably purchased from a reputable supplier, Shangda Biotechnology, with product number SD-0523-001. The fish oil of this invention has the effects of regulating blood lipids and promoting metabolism.

[0039] Based on the weight of the apple dietary fiber powder, the composition of this invention includes 5-15 parts of sodium alginate, preferably 10-15 parts, and more preferably 10 parts; the sodium alginate preferably has a size ≤80 mesh, and more preferably is sodium alginate that can pass through an 80-mesh sieve. The sodium alginate of this invention is preferably purchased from the official flagship store of YiYuanduo, product number 5383. The sodium alginate of this invention has excellent thickening, stability, water-holding capacity, gelling, emulsifying, and film-forming properties.

[0040] This invention uses a suitable ratio of apple dietary fiber powder, pea dietary fiber powder, and celery dietary fiber powder to form a high-fiber substance, and then combines it with a suitable ratio of cat grass powder, brewer's yeast, fish oil, and sodium alginate. The resulting composition can indirectly improve intestinal absorption capacity, improve intestinal health, alleviate intestinal inflammation, and promote digestion and absorption. The suitable size of the apple dietary fiber powder, pea dietary fiber powder, celery dietary fiber powder, cat grass powder, brewer's yeast, and sodium alginate allows the raw materials to mix better and exert their better effects.

[0041] The present invention also provides a method for preparing the composition described in the above technical solution, comprising the following steps:

[0042] The composition is obtained by mixing apple dietary fiber powder, pea dietary fiber powder, celery dietary fiber powder, cat grass powder, brewer's yeast, fish oil and sodium alginate in a certain proportion.

[0043] In this invention, the mixing process preferably further includes granulation to obtain a composition product in the form of soft granules; the diameter of the soft granules is preferably 0.5~1cm, and the thickness is preferably 0.5~1cm; the extrusion temperature of the granulation is preferably 40℃. The soft granules prepared by this invention with suitable diameter and thickness are easy for cats to swallow, and the suitable temperature allows for better granule formation.

[0044] The granulation method described in this invention is preferably dry granulation.

[0045] The present invention also provides the application of the composition described in the above technical solution or the composition prepared by the preparation method described in the above technical solution in the preparation of feed additives that promote intestinal health.

[0046] In this invention, the promotion of intestinal health preferably includes: alleviating intestinal inflammation and / or promoting digestion and absorption; the feed additive is preferably fed to cats.

[0047] The composition provided by this invention can alleviate intestinal inflammation and promote digestion and absorption, thereby improving intestinal health.

[0048] To further illustrate the present invention, the following detailed description, in conjunction with the accompanying drawings and embodiments, provides a composition for improving gut health, its preparation method, and its application, but these descriptions should not be construed as limiting the scope of protection of the present invention.

[0049] Example 1

[0050] A composition for improving gut health, comprising the following components in parts by weight: 15 parts apple dietary fiber powder, 15 parts pea dietary fiber powder, 10 parts celery dietary fiber powder, 15 parts cat grass powder, 5 parts brewer's yeast powder, 10 parts fish oil and 15 parts sodium alginate.

[0051] The composition is prepared as follows:

[0052] Apple dietary fiber powder, pea dietary fiber powder, celery dietary fiber powder, cat grass powder, brewer's yeast powder and sodium alginate were passed through an 80-mesh sieve to obtain the sieve products of different raw materials.

[0053] Weigh out the undersize material and fish oil of different raw materials according to the proportion, put them into a horizontal ribbon mixer for thorough mixing and uniform mixing. The mixing time is 30 minutes. When the coefficient of variation of the mixed material is 5%, the mixed material is obtained.

[0054] The mixed material is conveyed by a screw conveyor to a low-temperature cold pressing pellet mill, and soft pellets are extruded through the low-temperature cold pressing pellet mill. The diameter of the soft pellets is 0.5~1.0cm and the thickness is 0.5~1.0cm. The temperature of the extrusion zone of the low-temperature cold pressing pellet mill is 40℃, the temperature sensor of the cooling circulation pump is set to 50℃, and the power of the rotary cutting former is 25 Hz.

[0055] Example 2

[0056] A composition for improving gut health comprises the following components in parts by weight: 20 parts apple dietary fiber powder, 20 parts pea dietary fiber powder, 10 parts celery dietary fiber powder, 20 parts cat grass powder, 10 parts brewer's yeast powder, 10 parts fish oil, and 10 parts sodium alginate; the preparation method is the same as in Example 1.

[0057] Example 3

[0058] A composition for improving gut health comprises the following components in parts by weight: 25 parts apple dietary fiber powder, 25 parts pea dietary fiber powder, 15 parts celery dietary fiber powder, 15 parts cat grass powder, 15 parts brewer's yeast powder, 10 parts fish oil, and 15 parts sodium alginate; the preparation method is the same as in Example 1.

[0059] Comparative Example 1

[0060] A composition for improving gut health comprises the following components in parts by weight: 25 parts wheat dietary fiber, 25 parts pea dietary fiber powder, 15 parts celery dietary fiber powder, 15 parts cat grass powder, 15 parts brewer's yeast powder, 10 parts fish oil, and 15 parts sodium alginate; the preparation method is the same as in Example 1.

[0061] Comparative Example 2

[0062] A composition for improving gut health comprises the following components in parts by weight: 25 parts mulberry dietary fiber, 25 parts carrot dietary fiber powder, 15 parts celery dietary fiber powder, 15 parts cat grass powder, 15 parts brewer's yeast powder, 10 parts fish oil, and 15 parts sodium alginate; the preparation method is the same as in Example 1.

[0063] Comparative Application Example 1

[0064] 1. Safety evaluation test

[0065] The safety evaluation experiment used 30 healthy adult male cats weighing 1.99±0.44kg, which were randomly divided into three treatment groups: control group, Example 1 group, and Example 3 group. The control group was fed a normal diet (purchased from Zhejiang Kesheng Pet Food Co., Ltd., product number OPD), the Example 1 group was fed a normal diet supplemented with the composition prepared in Example 1, and the Example 3 group was fed a normal diet supplemented with the composition prepared in Example 3. The normal diet was fed at an amount of 90g / (cat·day) for all three groups, and the composition prepared in Example 1 and Example 3 was fed at an amount of 5g / (cat·day) for both groups.

[0066] On days 0, 32, and 64 of the experiment, fecal scores were assessed and the weights recorded. On days 32 and 64, blood was collected from the small saphenous vein on the lateral side of each cat's hind limb, and a portion of the whole blood was preserved and frozen at -20°C for subsequent testing of routine blood parameters. The remaining blood was allowed to stand at room temperature for 60 minutes in centrifuge tubes to allow for coagulation and stratification, then centrifuged at 3000 rpm and 4°C for 10 minutes. The supernatant was transferred to clean centrifuge tubes and frozen at -20°C for subsequent testing of blood biochemical parameters.

[0067] Stool scoring procedure: The Waltham stool scoring method is used as follows: Figure 1 As shown, specific trainees observed and scored the shape of fresh feces. The results are shown below. Figure 2 .Depend on Figure 2 It can be seen that there were no significant differences in fecal scores among the experimental groups on days 0, 32 and 64 (P>0.05), indicating that the control group, Example 1 group and Example 3 group had no negative impact on the intestinal health of the experimental cats during the experiment.

[0068] Weight measurement procedure: Place the test cat in the tare-free frame of the pet scale. After the scale stabilizes, take the reading to obtain the cat's weight. See the results below. Figure 3 .Depend on Figure 3 It can be seen that there were no significant differences among the experimental groups on days 0, 32 and 64 (P>0.05), indicating that the control group, Example 1 group and Example 3 group had no negative impact on the growth of the experimental cats during the experiment.

[0069] Hematological parameters were measured: the whole blood of the collected animals was measured using an automated blood cell analyzer, and the results are shown in Tables 1 and 2.

[0070] Table 1. Hematological parameters on day 32

[0071]

[0072] Table 2 Hematological parameters on day 64

[0073]

[0074] As shown in Tables 1 and 2, there were no significant differences (P>0.05) among the control group, Example 1 group, and Example 3 group on days 32 and 64, and the measurement results were all within the normal range.

[0075] Blood biochemical indicators were tested: serum samples were measured using a fully automated biochemical analyzer, and the results are shown in Tables 3 and 4.

[0076] Table 3. Blood biochemical indicators on day 32

[0077]

[0078] Table 4. Blood biochemical indicators on day 64

[0079]

[0080] As shown in Tables 3 and 4, there were no significant differences (P>0.05) among the control group, Example 1 group, and Example 3 group on days 32 and 64, and the measurement results were all within the normal range.

[0081] 2. Functional verification test

[0082] The Canine Inflammatory Bowel Disease Activity Index (CIBDAI) is a clinical scoring system consisting of six indicators that can indicate the intestinal health status of pets. The scoring criteria are shown in Table 5.

[0083] Table 5 Inflammatory Bowel Disease Activity Index

[0084]

[0085] Based on the CIBDAI score, the functional validation trial selected 24 adult male cats weighing 1.99±0.44 kg with mild inflammatory bowel disease. All cats had a CIBDAI score between 4 and 5 and had persistent enteritis symptoms, including mild vomiting, diarrhea and poor mental state, during the 21-day observation period.

[0086] The experiment was divided into four treatment groups: control group, comparative example 1, comparative example 2, and example 3. The control group was fed a normal diet (purchased from Zhejiang Kesheng Pet Food Co., Ltd., product number OPD). Comparative example 1 was fed a normal diet supplemented with the composition prepared in comparative example 1. Comparative example 2 was fed a normal diet supplemented with the composition prepared in comparative example 2. Example 3 was fed a normal diet supplemented with the composition prepared in example 3. The normal diet was fed at an amount of 90g / (animal·day) to all three groups. The compositions prepared in comparative examples 1 and 2 and the composition prepared in example 3 were fed at an amount of 5g / (animal·day) to all three groups.

[0087] 1) On days 0, 21, and 42 of the experiment, fecal scores were assessed and weighed, and the results were recorded. The measurement method was the same as in step 1. The results are shown in [see attached table]. Figure 4 and Figure 5 .

[0088] Depend on Figure 4 It was found that there were no significant differences among the experimental groups on days 0 and 21 (P>0.05). On day 42, compared with the control group, the body weight of Comparative Example 1, Comparative Example 2, and Example 3 was significantly higher (P≤0.05), and the body weight of Comparative Example 1 was significantly higher than that of Comparative Example 2 (P≤0.05). There was no significant difference between Example 3 and Comparative Example 1 and Comparative Example 2 (P>0.05), indicating that on day 42, both the comparative example groups and Example 3 could improve the growth and health status of the experimental cats.

[0089] Depend on Figure 5It can be seen that on day 0, there were no significant differences among the experimental groups (P>0.05), indicating that at the beginning of the experiment, the control group, comparative group, and Example 3 group were all at the same level of intestinal health. On day 21, there were no significant differences between comparative group 1 and Example 3 (P>0.05), between comparative group 1 and comparative group 2 (P≤0.05), and between the control group and comparative group 2 (P≤0.05). Compared with the control group, the fecal scores of comparative group 1 and Example 3 were significantly higher. (P≤0.05) The fecal score of the Example 3 group was significantly higher than that of the Comparative Example 2 group, indicating that the Example 3 group can play a role in promoting intestinal health. On day 42, compared with the control group, the fecal scores of the Comparative Example 1 group, the Comparative Example 2 group, and the Example 3 group were all significantly increased (P≤0.05). The fecal score of the Comparative Example 1 group was significantly higher than that of the Comparative Example 2 group (P≤0.05), and the fecal score of the Example 3 group was significantly higher than that of the Comparative Example 1 group and the Comparative Example 2 group (P≤0.05), indicating that the Example 3 group has a role in promoting intestinal health.

[0090] 2) Fresh feces were collected from each experimental cat on days 0, 21, and 42 of the experiment and stored at -20℃ for fecal odor analysis. The ammonia concentration in the feces was determined using a ZG-1 manual hazardous gas sampler. Results are shown below. Figure 6 See Table 6.

[0091] Table 6 Odor of the Test Cat Feces

[0092]

[0093] Fecal odor is an important indicator of a cat's gut health; when a cat has indigestion or gastrointestinal dysfunction, the ammonia content in its feces will increase. Figure 6 As shown in Table 6, on day 0, there was no significant difference in ammonia content in feces among the experimental groups (P>0.05), indicating that at the beginning of the experiment, the control group, comparative group, and Example 3 group were all at the same level of intestinal health. On day 21, the ammonia content in feces of Example 3 group, comparative group 1, and comparative group 2 was significantly lower than that of the control group (P≤0.05), while there was no significant difference among comparative group 1, comparative group 2, and Example 3 group (P>0.05). On day 42, the ammonia content in feces of the control group was significantly higher than that of the other three groups (P≤0.05), and the ammonia content of comparative group 2 was significantly higher than that of comparative group 1, comparative group 2, and Example 3 group (P≤0.05), while there was no significant difference between comparative group 1 and Example 3 group (P>0.05). The results indicate that both comparative group 1 and Example 3 group have a promoting effect on intestinal health, and the effects of the two groups are the same.

[0094] 3) On day 42 of the experiment, blood was collected from the small saphenous vein on the lateral side of the hind limbs of each experimental cat. The blood was allowed to stand at room temperature for 60 minutes in centrifuge tubes to coagulate and separate into layers. Then, it was centrifuged at 3000 rpm and 4°C for 10 minutes. The supernatant was transferred to a clean centrifuge tube and stored at -20°C for subsequent testing of antioxidant and immune indicators, as well as gut health-related indicators. Antioxidant and immune-related indicators included: malondialdehyde (MDA), superoxide dismutase (SOD), immunoglobulin A (IgA), immunoglobulin G (IgG), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10). Gut health indicators included: lipopolysaccharide (LPS), diamine oxidase (DAO), fatty acid-binding protein (i-FABP), and lactate (D-LA). The detection procedure was as follows: Centrifuged serum collected during the experiment was analyzed using enzyme-linked immunosorbent assay (ELISA). The results are shown in […]. Figure 7 The enzyme-linked immunosorbent assay (ELISA) kits used for the above-mentioned indicators were purchased from Bethyl Laboratories and Neoscientific, USA. The kits for detecting DAO and i-FABP were purchased from Neoscientific, while the kits for the other indicators were purchased from Bethyl Laboratories.

[0095] Depend on Figure 7It can be seen that, for IL-1β, the content in the control group was significantly higher than that in the comparative example 1 group and the example 3 group (P≤0.05), the content in the comparative example 2 group was significantly higher than that in the example 3 group (P≤0.05), there was no significant difference between the control group and the comparative example 2 group (P>0.05), and there was no significant difference between the comparative example 1 group and the example 3 group (P>0.05), indicating that the example 3 group can play a role in reducing intestinal inflammation. Regarding IL-10, the level in the control group was significantly lower than that in Comparative Example 1, Comparative Example 2, and Example 3 (P≤0.05). The level in Comparative Example 2 was significantly lower than that in Comparative Example 1 and Example 3 (P≤0.05), while there was no significant difference between Comparative Example 1 and Example 3 (P>0.05). This indicates that Comparative Example 1 and Example 3 can promote gut health. Regarding TNF-α and D-LA, the level in the control group was significantly higher than that in the other three groups (P≤0.05). The level in Comparative Example 2 was significantly higher than that in Comparative Example 1 and Example 3 (P≤0.05), while there was no significant difference between Comparative Example 1 and Example 3 (P>0.05). The results showed that both Comparative Example 1 and Example 3 could reduce inflammation, and the effects of Comparative Example 1 and Example 3 were the same. For DAO, i-FABP, and IL-6, the levels in the control group and Comparative Example 2 were significantly higher than those in Comparative Example 1 and Example 3 (P≤0.05), while there was no significant difference between Comparative Example 1 and Example 3 (P>0.05), and no significant difference between the control group and Comparative Example 2 (P>0.05). This indicates that the degree of intestinal damage and inflammation in Comparative Example 1 and Example 3 was lower than that in the control group, which is beneficial for promoting intestinal health. For IgG and LPS, there were no significant differences among the experimental groups (P>0.05). Regarding IgA, the control group showed significantly higher levels than Comparative Example 1, Comparative Example 2, and Example 3 (P≤0.05), while Comparative Example 2 showed significantly higher levels than Comparative Example 1 and Example 3 (P≤0.05), and Comparative Example 1 showed significantly higher levels than Example 3 (P≤0.05), indicating that Example 3 could reduce intestinal inflammation levels. Regarding MDA, the control group showed significantly higher levels than Comparative Example 1, Comparative Example 2, and Example 3 (P≤0.05), while Comparative Example 2 showed significantly higher levels than Example 3 (P≤0.05), and Comparative Example 1 showed significantly lower levels than the control group. There was no significant difference between Example 2 and Example 3 (P>0.05), and no significant difference between Comparative Example 1 and Example 3 (P>0.05), indicating that Example 3 reduced inflammation levels and promoted gut health compared with the control group. As for SOD, the levels in the control group and Comparative Example 2 were significantly lower than those in Comparative Example 1 and Example 3 (P≤0.05), and there was no significant difference between Comparative Example 1 and Example 3 (P>0.05). There was no significant difference between the control group and Comparative Example 2 (P>0.05), indicating that both Comparative Example 1 and Example 3 promoted gut health.

[0096] 4) On day 42 of the experiment, the fecal sample was stored at -80℃ for analysis of fecal microbial composition and quantitative analysis of targeted short-chain fatty acids (SCFAs). The content of targeted SCFAs in feces was determined by gas chromatography as follows: 1g of fecal sample was placed in 15mL of double-distilled water and stirred thoroughly with a glass rod to dissolve the feces and form a homogeneous suspension. The suspension was then sonicated for 30min and centrifuged at 12000×g for 10min. The supernatant was collected after filtration through a 0.22μm filter screen. 1µL of the supernatant was injected into a capillary column (60m×250µm×0.25µm) with cyanopropyl methylsiloxane as the stationary phase. The temperature of the injection port and detector was maintained at 240℃. Nitrogen was used as the carrier gas at a flow rate of 2.0mL / min. The peak areas of acetic acid, propionic acid, and butyric acid were substituted into the regression equation of the standard curve established using the standards to obtain the data. The results are shown in [Figure number missing]. Figure 8 .

[0097] Depend on Figure 8 It was found that the concentration of acetic acid in feces did not differ significantly between the control group and Comparative Examples 1 and 2 (P>0.05), nor between Comparative Example 1 and Example 3 (P>0.05). The concentration of acetic acid in feces in the control group and Example 2 was significantly lower than that in Example 3 (P≤0.05). The concentration of butyric acid in feces in Comparative Example 1 and Example 3 was significantly higher than that in the control group and Comparative Example 2 (P≤0.05), but there was no significant difference in butyric acid concentration in feces between Comparative Example 1 and Example 3 (P>0.05). There were no significant differences between the treatment groups and Example 2 (P>0.05); the levels of propionic acid, isobutyric acid, valeric acid, and isovaleric acid remained unchanged among the treatment groups (P>0.05); the main mechanism of altered SCFA composition involves changes in the gut microbiota, and these results are attributed to the significantly increased abundance of acetic acid- or butyric acid-producing bacteria induced by AVA. Acetic acid can serve as a source of butyric acid synthesis, therefore, increased acetic acid levels can further lead to increased butyric acid content; butyric acid has the effect of inhibiting the activation of nuclear factor κB and reducing the production of inflammatory factors, thereby alleviating local inflammatory responses in the gut. Therefore, the experiment shows that both Example 3 and Comparative Example 1 have anti-inflammatory and anti-allergic effects, and the anti-inflammatory and anti-allergic effects of Example 3 are superior to those of the Comparative Example 1.

[0098] Fecal microbial composition analysis: The fecal microbial composition of cats was analyzed using the Illumina HiSeq high-throughput sequencing platform. Genomic DNA was extracted from cecal digesta / feces using the QIAamp DNA extraction kit (Qiagen, Germany), following the manufacturer's instructions. After DNA extraction, the integrity of the fecal DNA was assessed using agarose gel electrophoresis. PCR amplification of the conserved V3-V4 region of the 16S rRNA gene in the extracted fecal DNA was performed using universal primers with fusion sample-specific barcode sequences. The primer sequences for the target fragment are as follows:

[0099] 341F: 5'-CCTAYGGGRBGCASCAG-3', SEQ ID NO.1;

[0100] 806R: 5'-GGACTACNNNGGGTATCTAAT-3', SEQ ID NO. 2.

[0101] The obtained PCR products were analyzed using agarose gel electrophoresis to detect primer specificity. The target bands were recovered by gel extraction using the AxyPrep gel extraction kit (Axygen, USA) and quantified using a Qubit 2.0 quantitative PCR system (Thermo Fisher Scientific, USA). Based on the Illumina HiSeq high-throughput sequencing platform, libraries were constructed and subjected to 2×250bp paired-end sequencing. Based on the overlap relationship between the sequenced PE reads, two sequences were spliced ​​using FLASH software. PANDASeq was used for sequence quality control and filtering. After sample splitting, UPARSE software was used to cluster the processed high-quality sequences based on 97% sequence similarity. During clustering, UCHIME was used to remove chimeras, obtaining representative sequences. Based on the QIIME 2.0 platform, the RDP classifier Bayesian algorithm was used to compare the representative sequences with 97% similarity with the Silva database. The community species composition of each sample was statistically analyzed on each taxonomic level. Species richness and evenness indices were calculated using the MOTHUR program. Using the QIIME 2.0 platform, the Bary-Curtis and Jaccard distances were calculated, and PCoA analysis was performed to visualize the differences in microbial community structure between groups. The results are shown below. Figures 9-11 .

[0102] Depend on Figure 9It can be seen that, at the phylum level, the abundance of Firmicutes in the comparative and control groups was significantly higher than that in the Example 3 group (P≤0.05), while there was no significant difference between the control and comparative groups (P>0.05). Firmicutes microorganisms are associated with metabolic diseases, and an increase in these bacteria may lead to obesity and intestinal inflammation. Therefore, compared with the control and comparative groups, the Example 3 group can more effectively maintain intestinal health. The abundance of Actinobacteriota microorganisms in the Example 3 group was significantly higher than that in the comparative and control groups (P≤0.05), while there was no significant difference between the control and comparative groups (P>0.05). Actinobacteriota microorganisms are one of the important sources of acetic acid and butyric acid production in the intestine, which can alleviate intestinal inflammation. Therefore, the Example 3 group is more able to protect intestinal health by inducing an increase in the abundance of acetic acid or butyric acid-producing bacteria.

[0103] Depend on Figure 10 It was found that the abundance of the Eggerthellaceae family in both the Example 3 group and the comparative group was significantly higher than that in the control group (P≤0.05), while there was no significant difference between the Example 3 group and the comparative group (P>0.05). At the family level, the Eggerthellaceae family has anti-inflammatory and oxidative stress response effects and also has a certain regulatory effect on intestinal flora imbalance. Therefore, both the Example 3 group and the comparative group can alleviate intestinal inflammation to a certain extent. The Atopobiaceae and Coriobacteriaceae families produce acetic acid during digestion, which has the effect of reducing inflammatory response. The abundance of Atopobiaceae and Coriobacteriaceae families in the Example 3 group was significantly higher than that in the control group and the comparative group (P≤0.05), while there was no significant difference between the comparative group and the control group (P>0.05), indicating that the Example 3 group can effectively alleviate intestinal inflammation.

[0104] Depend on Figure 11It was found that at the genus level, Collinsella was negatively correlated with intestinal diarrhea. The abundance of Collinsella in the Example 3 group was significantly higher than that in the control group and the comparative group (P≤0.05), while there was no significant difference between the comparative group and the control group (P>0.05). This indicates that the Example 3 group was more effective in relieving intestinal diarrhea than the control group and the comparative group. Olsenella can enhance the immune response of the intestine and reduce the occurrence of intestinal inflammation. The abundance of *Olsenella* in Example 3 group was significantly higher than that in the control group (P≤0.05). There was no significant difference between the comparative group and the control group and Example 3 group (P>0.05), indicating that Example 3 group was more effective in enhancing intestinal immune response and protecting intestinal health than the control group, while the improvement effect of the comparative group was in between. The decrease in the abundance of *Libanicoccus* genus is related to the development of diabetes. The abundance of *Libanicoccus* genus in Example 3 group was significantly higher than that in the control group and the comparative group (P≤0.05), while there was no significant difference between the comparative group and the control group (P>0.05), indicating that Example 3 group was more beneficial to the digestion and absorption of pets.

[0105] In summary, both the comparative group and the Example 3 group can alleviate intestinal inflammation and protect intestinal health, but the efficacy of the product in Example 3 group is significantly better than that in the comparative group.

[0106] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Use of a composition for improving intestinal health in the preparation of a feed additive for promoting intestinal health, characterized in that: the composition is composed of the following components in parts by mass: apple dietary fiber powder 25 parts, pea dietary fiber powder 25 parts, celery dietary fiber powder 15 parts, cat grass powder 15 parts, beer yeast 15 parts, fish oil 10 parts, and sodium alginate 15 parts; the preparation method of the composition consists of the following steps: mixing apple dietary fiber powder, pea dietary fiber powder, celery dietary fiber powder, cat grass powder, beer yeast, fish oil, and sodium alginate in proportion to obtain the composition; the size of apple dietary fiber powder, pea dietary fiber powder, celery dietary fiber powder, cat grass powder, beer yeast, and sodium alginate in the composition is capable of passing through an 80-mesh sieve; the promotion of intestinal health includes relieving intestinal inflammation and / or promoting digestion and absorption; the feeding object of the feed additive includes cats; the composition after mixing further includes granulation to obtain a soft granular composition product; the diameter of the soft granules is 0.5-1 cm, and the thickness is 0.5-1 cm; the extrusion temperature of the granulation is 40-80°C.

2. The use according to claim 1, wherein the composition is used in the preparation of a feed additive for promoting intestinal health in cats.

3. The use according to claim 1 or 2, wherein the composition is used in the preparation of a feed additive for relieving intestinal inflammation in cats.

4. The use according to any one of claims 1-3, wherein the composition is used in the preparation of a feed additive for promoting digestion and absorption in cats.

5. The use according to any one of claims 1-4, wherein the composition is used in the preparation of a feed additive for improving the intestinal health of cats. ​ 2. Use according to claim 1, characterized in that, ​ 3. Use according to claim 2, characterized in that, ​

Images